Nieng Yan Appointed As Academic Committee Member of Chinese Academy of Medical Sciences
On April 15, Nieng Yan, a Chinese structural biologist and the Shirley M. Tilghman Professor of Molecular Biology at Princeton University, was elected as a member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences.
Also appointed were Liu Guanghui from the Institute of Zoology, Chinese Academy of Sciences, Hu Zhibin from Nanjing Medical University, Song Baoliang from Wuhan University, and Fan Chunhai from Shanghai Jiao Tong University. Their research fields cover aging and regenerative medicine, molecular epidemiology, structural biology, and biochemistry.
The Academic Advisory Committee of the Chinese Academy of Medical Sciences was established in August 2019. Its primary responsibility is to provide consultation on major issues related to national medical health development, especially key and difficult problems in national scientific and technological innovation system construction. The committee currently has 276 members.
SEE ALSO: Chinese Scientist Nieng Yan Assigned as Director of Shenzhen Bay Laboratory
On November 1, 2022, Nieng Yan announced that she would resign from her position at Princeton University to become the founding dean of the Shenzhen Medical Academy of Research and Translation (SMART). This announcement attracted wide attention.
On December 10, 2022, SMART was unveiled with Nieng Yan receiving an appointment letter as dean. The institute is mainly responsible for preparing for various projects and has departments including Research Department, Research Platform, Special Fund Management, Education and Communication, Operation Management, and Infrastructure Construction.
This year, Nieng Yan was appointed as the director of Shenzhen Bay Laboratory on March 22. It is a key strategic deployment for Guangdong Province and Shenzhen to build leading international and domestic science and technology innovation centers in the Guangdong-Hong Kong-Macao Greater Bay Area.
With a view on the global science and technology frontiers and its mission to support China’s National Strategic Plan layout, the institute is committed to solving major scientific problems collaboratively. Focusing on the prevention, diagnosis, and treatment of cancer, metabolic syndromes, cardiovascular diseases, neurodegenerative disorders, and other major diseases, it features BT+IT integration and multidisciplinary collaborations to develop strength in Bioinformatics, Innovative Drug, Biomedical Engineering, and other biomedical fields.